CSL Ltd. is a biopharmaceutical company, which engages in the research, development, manufacture, marketing and distribution of biopharmaceutical and allied products. It operates through the CSL Behring and Seqirus segments. The CSL Behring segment provides plasma-derived and recombinant products, and operates plasma collection networks through CSL Plasma. The Seqirus segment manufactures and distributes non-plasma biotherapeutic products and develops influenza related products. The company was founded on November 2, 1961 and is headquartered in Parkville, Australia.
Company profile
Ticker
CSLLY, CMXHF
Exchange
Website
CEO
Paul Roger Perreault
Employees
Location
SEC CIK
CSLLY stock data
Latest filings (excl ownership)
F-6EF
Automatic registration for ADRs (foreign)
21 Jun 22
EFFECT
Notice of effectiveness
9 Jun 14
F-6
Registration for ADRs (foreign)
28 May 14
F-6EF
Automatic registration for ADRs (foreign)
4 Aug 11
F-6EF
Automatic registration for ADRs (foreign)
17 Jun 10
F-6EF
Automatic registration for ADRs (foreign)
4 Nov 08
F-6EF
Automatic registration for ADRs (foreign)
15 Oct 08
REGDEX
Notice of sale of securities
22 Dec 03
Transcripts
Latest ownership filings
Institutional ownership, Q2 2022
0.0% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 1 |
Opened positions | 1 |
Closed positions | 0 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 832.59 mm |
Total shares | 4.50 k |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Paradigm Asset Management | 4.50 k | $832.59 mm |
News
GSK, Sanofi, And CSL Secure US Government Fund To Boost Bird Flu Vaccine Production: Report
4 Oct 24
Arcturus Therapeutics/CSL Partnered COVID-19 Vaccine Surpasses Pfizer's Comirnaty Shot, Even At Lower Doses
30 Sep 24
Akebia And CSL Vifor Have Terminated The License Agreement Providing For The Payment Of Royalties By Akebia To CSL Vifor On Vafseo (Vadadustat) U.S. Net Product Sales. As A Result, Akebia Regained Full Rights To Sell Vafseo In The U.S.
11 Jul 24
Press releases
CSL Seqirus, a Global Leader in Pandemic Preparedness, Announces Sixth BARDA Award in Response to Avian Influenza
4 Oct 24
CSL Seqirus Presents Real-World Evidence at OPTIONS XII Conference Highlighting Effectiveness of Influenza Vaccinations
1 Oct 24
Self-Amplifying mRNA COVID-19 Vaccine Demonstrates Superior Immune Response Compared with mRNA Vaccine at 12 Months Post-Vaccination
30 Sep 24
CSL Seqirus, a Global Leader in Pandemic Preparedness, Announces Fifth BARDA Award in Response to Avian Influenza Outbreak
25 Sep 24
Veltassa® (patiromer) approved in Japan for the treatment of adults with hyperkalemia
24 Sep 24